Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer

Study:

A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal

Rationale:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining radiation therapy with chemotherapy may kill more tumor cells. It is not yet known whether fluorouracil and mitomycin plus radiation therapy is more effective than fluorouracil and cisplatin plus radiation therapy for anal cancer.

Purpose:

This randomized phase III trial is studying fluorouracil and mitomycin plus radiation therapy to see how well it works compared to fluorouracil and cisplatin plus radiation therapy in treating patients with stage II or stage III anal cancer.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Anal Cancer Drug: cisplatin
Drug: fluorouracil
Drug: mitomycin C
Radiation: radiation therapy
Phase 3

Verified by Radiation Therapy Oncology Group November, 2013

Sponsored by: Radiation Therapy Oncology Group
Information provided by: Radiation Therapy Oncology Group
ClinicalTrials.gov identifier: NCT00003596

Study Type: Interventional

Study Design: Allocation: Randomized, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Jaffer A. Ajani, MD., Study Chair
Al B. Benson, MD, FACP., Study Chair
Joel E. Tepper, MD., Study Chair
John S. MacDonald, MD., Study Chair
Michael G. Haddock, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site